Research programme: serotonin 2 receptor antagonists - AnaMar
Alternative Names: AM260; AM260 TASS; Am260, TASS; AMAP 312; AMAP332Latest Information Update: 22 Feb 2023
At a glance
- Originator AnaMar Medical
- Developer AcurePharma; AnaMar AB
- Class Analgesics; Anti-inflammatories; Antifibrotics; Antirheumatics; Small molecules
- Mechanism of Action Serotonin 2B receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Idiopathic pulmonary fibrosis; Inflammatory pain; Osteoarthritis; Rheumatoid arthritis
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Inflammatory pain in Sweden (PO) (AnaMar AB pipeline, February 2023)
- 22 Feb 2023 Discontinued - Preclinical for Inflammatory pain in Sweden (Topical) (AnaMar AB pipeline, February 2023)
- 22 Feb 2023 Discontinued - Preclinical for Osteoarthritis in Sweden (PO) (AnaMar AB pipeline, February 2023)